# Mantis Biotechnology Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mantis-biotechnology

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.mantisbiotech.com/
- Total disclosed funding: $6.3M
- Latest round: Seed (Dec 19, 2025)
- Investors on record: 5

## About

Mantis Biotechnology Corporation specializes in creating a revolutionary data platform tailored for the life sciences sector, enabling efficient analysis of complex biological and clinical datasets across various systems.Founded in 2025 and headquartered in San Francisco, US, Mantis Biotechnology Corporation provides innovative solutions for the life sciences industry. The company's CEO, Georgia Witchel, leads the organization as it focuses on leveraging data to enhance decision-making in clinical trials and biomedical research. Mantis raised USD 6.3 mn in SEED funding in December 2025, led by Decibel, with participation from multiple investors, bringing the total amount raised to USD 6.3 mn and a current company valuation of USD 17.51 mn.Mantis offers a groundbreaking data platform specifically designed for the life sciences sector, encoding biological and clinical meaning into reusable datasets. This platform allows organizations to efficiently analyze vast amounts of biological, clinical, and operational data generated across specialized systems like Electronic Data Capture and Clinical Trial Management Systems. It provides canonical, versioned datasets that persist across teams, enabling users to address complex questions without needing to reconstruct pipelines for every analysis. Mantis primarily serves customers in North America and Europe, focusing on firms involved in clinical trials and biomedical research.Mantis generates revenue through a subscription-based model that enables clients to access its domain-aware data platform and associated analytics tools. Clients enter agreements for access to reusable datasets and tailored analytics solutions, improving operational efficiency and compliance. Pricing structures accommodate various client sizes, with plans tailored for the specific needs within the life sciences sector. Mantis ensures ongoing support and updates, working closely with teams to implement custom integrations and maintain high standards of data governance. Key offerings include its versioned datasets and analytics suite, which are essential for organizations aiming to leverage data effectively.Mantis Biotechnology Corporation plans to utilize its recent funding to build infrastructure, enhance its data platform, scale operations responsibly, and broaden its market reach. The company is focusing on launching new products in the near future while specifically targeting expansion into new geographic markets, although details about the specific regions and timelines for expansion were not disclosed. The recent SEED funding of USD 6.3 mn, raised in December 2025, will support these growth initiatives.

## Funding rounds

- Seed, Dec 19, 2025, $6.3M — Y Combinator, Pioneer Fund, Decibel, StoryHouse Ventures, Spot VC

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed
- Decibel (https://capitalatlas.ai/funds/decibel) — Seed
- StoryHouse Ventures (https://capitalatlas.ai/funds/storyhouse-ventures) — Seed
- Spot VC (https://capitalatlas.ai/funds/spot-vc) — Seed